OTC Markets OTCPK - Delayed Quote USD

Novo Nordisk A/S (NONOF)

Compare

112.00

+7.00

(+6.67%)

As of 11:40 am GMT-5. Market open.

Key events

Advanced chart

Loading Chart for NONOF

9/21 12:03 PM

DELL

Previous close 105.00
Open 112.50
Bid 106.00 x 47300
Ask 112.50 x 40000
Day's range 107.30 - 112.50
52-week range 93.80 - 149.55
Volume 360
Avg. Volume 37,160
Market cap (intra-day) 514.882B
Beta (5Y monthly) 0.15
PE ratio (TTM) 38.23
EPS (TTM) 2.93
Earnings date 6 Nov 2024
Forward dividend & yield 1.45 (1.36%)
Ex-dividend date 15 Aug 2024
1y target est --

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

69,260

Full-time employees

31 December

Fiscal year ends

Healthcare

Sector

Drug Manufacturers - General

Industry

How to play healthcare stocks on Trump's win

Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook

Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar 76%

Novo Nordisk Q3 earnings: Wegovy sales soar 79% year-over-year

Novo Nordisk Posts Mixed Results, Adding to Jitters About Weight-Loss Drugs

Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand

Novo Nordisk CFO says 2025 sales could see high-teens percentage growth

Novo Nordisk: Q3 Earnings Snapshot

Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump

How to play healthcare stocks on Trump's win

Healthcare stocks, particularly those with exposure to privately managed Medicare Advantage plans, are in focus after President-elect Donald Trump's victory. Jefferies healthcare services equity research analyst Brian Tanquilut joins Seana Smith and Brad Smith on Morning Brief to discuss what healthcare investors expect from a second Trump term. “There has been a lot of pressure over the last couple of years from the Biden administration, and these Medicare Advantage plans," Tanquilut says, adding, “The expectation is that because the Republican Party is very pro-Medicare Advantage, they'd rather have these private plans run the Medicare program away from the government-run program that we have right now through traditional Medicare, that the pressure on these plans will ease going forward.” The analyst says, “I think the reactions that we're seeing today are about appropriate, given that expectation and the sentiment that we've seen in the group.” He says going forward, “one of the things that we're watching really closely are these health insurance exchange subsidies,” which Congress needs to act on when they expire at the end of 2025. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.